The Experts below are selected from a list of 285 Experts worldwide ranked by ideXlab platform
Michael J. Gait - One of the best experts on this subject based on the ideXlab platform.
-
Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery.
Biochimica et Biophysica Acta (BBA) - Biomembranes, 2006Co-Authors: John J. Turner, Martin M. Fabani, Andrey A. Arzumanov, Gabriela D. Ivanova, Michael J. GaitAbstract:New candidates for development as potential drugs or Virucides against HIV-1 infection and AIDS continue to be needed. The HIV-1 RNA leader sequence has many essential functional sites for virus replication and regulation that includes several highly conserved sequences. The review describes the historical context of targeting the HIV-1 RNA leader sequence with antisense phosphorothioate oligonucleotides, such as GEM 91, and goes on to describe modern approaches to targeting this region with steric blocking oligonucleotide analogues having newer and more advantageous chemistries, as well as recent studies on siRNA, towards the attainment of antiviral activity. Recent attempts to obtain improved cell delivery are highlighted, including exciting new developments in the use of peptide conjugates of peptide nucleic acid (PNA) as potential Virucides.
-
Review Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: Chemistry and cell delivery
2005Co-Authors: John J. Turner, Martin M. Fabani, Andrey A. Arzumanov, Gabriela Ivanova, Michael J. GaitAbstract:New candidates for development as potential drugs or Virucides against HIV-1 infection and AIDS continue to be needed. The HIV-1 RNA leader sequence has many essential functional sites for virus replication and regulation that includes several highly conserved sequences. The review describes the historical context of targeting the HIV-1 RNA leader sequence with antisense phosphorothioate oligonucleotides, such as GEM 91, and goes on to describe modern approaches to targeting this region with steric blocking oligonucleotide analogues having newer and more advantageous chemistries, as well as recent studies on siRNA, towards the attainment of antiviral activity. Recent attempts to obtain improved cell delivery are highlighted, including exciting new developments in the use of peptide conjugates of peptide nucleic acid (PNA) as potential Virucides
M. B. Stope - One of the best experts on this subject based on the ideXlab platform.
-
Virucide properties of cold atmospheric plasma for future clinical applications
Journal of Medical Virology, 2017Co-Authors: Martin Weiss, G. Daeschlein, A. Kramer, M. Burchardt, S. Brucker, Diethelm Wallwiener, M. B. StopeAbstract:Cold atmospheric plasma (CAP) has been repeatedly identified to bear powerful microbicidal efficacy on bacteria including multidrug resistant organisms and fungi on non-living surfaces, in biofilms as well as on contaminated and infected tissues. CAP furthermore was found to stimulate wound healing in chronic wounds and exerted anti-neoplastic effects on numerous tumor entities. Thus, CAP represents a promising medical tool for many clinical and therapeutic issues. Studies about CAP effects on virus particles recently were in arrears, but to date increasingly move into the focus of interest. Apparently, CAP treatment is followed by a promising virus inactivation and contributes to tissue regeneration. Here we review the current state of science concerning the so far investigated CAP effects on different virus species and virus-associated disorders. This article is protected by copyright. All rights reserved
-
Virucide properties of cold atmospheric plasma for future clinical applications
Journal of medical virology, 2017Co-Authors: Martin Weiss, G. Daeschlein, A. Kramer, M. Burchardt, S. Brucker, Diethelm Wallwiener, M. B. StopeAbstract:Cold atmospheric plasma (CAP) has been repeatedly identified to bear powerful microbicidal efficacy on bacteria including multidrug resistant organisms and fungi on non-living surfaces, in biofilms as well as on contaminated and infected tissues. CAP furthermore was found to stimulate wound healing in chronic wounds and exerted anti-neoplastic effects on numerous tumor entities. Thus, CAP represents a promising medical tool for many clinical and therapeutic issues. Studies about CAP effects on virus particles recently were in arrears, but to date increasingly move into the focus of interest. Apparently, CAP treatment is followed by a promising virus inactivation and contributes to tissue regeneration. Here we review the current state of science concerning the so far investigated CAP effects on different virus species and virus-associated disorders. J. Med. Virol. 89:952-959, 2017. © 2017 Wiley Periodicals, Inc.
L. Haddioui - One of the best experts on this subject based on the ideXlab platform.
-
activite Virucide in vitro d un extrait de cypres sur des virus humains et bovins
Phytopathology, 2018Co-Authors: I Guinobert, L. Haddioui, V Bardot, Lucile Berthomier, Isabelle Ripoche, C Faivre, H BelkhelfaAbstract:L’objectif etait de realiser l’empreinte phytochimique par HPTLC et d’identifier par LC/MS les principaux composes d’un extrait hydroethanolique de cones frais de cypres (Cupressus sempervirens L.) puis d’evaluer l’activite Virucide de cet extrait sur quatre virus infectant l’Homme et trois virus bovins. L’analyse phytochimique a montre la presence de tanins, de flavonoides, d’acides amines et de glucides. A 40 % (v/v), au contact des virus pendant 60 minutes a 37 °C, l’extrait a eu une activite Virucide sur le coronavirus, le virus parainfluenza de type 3, le virus respiratoire syncytial bovin et le rotavirus bovin. A 80 % (v/v), l’extrait a eu une activite Virucide sur le virus influenza A-H1N1, le rhinovirus et l’herpesvirus bovin de type 1. Ces resultats invitent a poursuivre les travaux sur cet extrait de cypres et a explorer ses effets antiviraux in vivo.
-
Étude de l’activité Virucide in vitro des Gouttes aux Essences® sur le virus para-influenzae de type 3
Phytothérapie, 2009Co-Authors: L. Haddioui, B. Fabre, P. BruelAbstract:Le traitement par les huiles essentielles des infections respiratoires limite le recours systematique aux antibiotiques (Phytotherapie 6 (2004) 175–9). Plusieurs virus sont responsables de ces infections virales respiratoires: virus influenza, virus respiratoire syncytial, virus para-influenzae, adenovirus, rhinovirus... Cette etude a consiste a mettre en evidence l’activite Virucide in vitro du produit Gouttes aux Essences®, complexe de cinq huiles essentielles vis-a-vis du virus para-influenzae de type 3, virus a ARN enveloppe appartenant au genre respirovirus. L’evaluation de l’activite Virucide des huiles essentielles a ete realisee selon la norme NF EN 14476 + A1 (janvier 2007, phase 2, etape 1). Les huiles essentielles diluees a 20 et 80 %, mises en contact avec le virus para-influenzae de type 3 durant 60 minutes a 20 °C, presentent une activite Virucide significative. Ce travail confirme l’interet et la pertinence de la prise en charge in vivo des infections virales respiratoires par les huiles essentielles qui peuvent ainsi completer l’arsenal therapeutique et limiter le recours indu aux antibiotiques.
-
etude de l activite Virucide in vitro des gouttes aux essences sur le virus para influenzae de type 3
Sozial-und Praventivmedizin, 2009Co-Authors: L. Haddioui, B. Fabre, P. BruelAbstract:Le traitement par les huiles essentielles des infections respiratoires limite le recours systematique aux antibiotiques (Phytotherapie 6 (2004) 175–9). Plusieurs virus sont responsables de ces infections virales respiratoires: virus influenza, virus respiratoire syncytial, virus para-influenzae, adenovirus, rhinovirus... Cette etude a consiste a mettre en evidence l’activite Virucide in vitro du produit Gouttes aux Essences®, complexe de cinq huiles essentielles vis-a-vis du virus para-influenzae de type 3, virus a ARN enveloppe appartenant au genre respirovirus. L’evaluation de l’activite Virucide des huiles essentielles a ete realisee selon la norme NF EN 14476 + A1 (janvier 2007, phase 2, etape 1). Les huiles essentielles diluees a 20 et 80 %, mises en contact avec le virus para-influenzae de type 3 durant 60 minutes a 20 °C, presentent une activite Virucide significative. Ce travail confirme l’interet et la pertinence de la prise en charge in vivo des infections virales respiratoires par les huiles essentielles qui peuvent ainsi completer l’arsenal therapeutique et limiter le recours indu aux antibiotiques.
-
Étude de l’activité Virucide in vitro des Gouttes aux Essences® sur le virus para-influenzae de type 3
Phytothérapie, 2009Co-Authors: L. Haddioui, B. Fabre, P. BruelAbstract:Respiratory tract infection treatment with essential oils limits the use of antibiotics (Phytothérapie 6 (2004) 175–9). Several different viruses cause those respiratory tract infections: influenza viruses, respiratory syncytial virus, para-influenza viruses, adenoviruses and rhinoviruses... The aim of this study was to show the virucidal action of Gouttes aux Essences®, a complex of five essential oils, against para-influenza type 3 virus, an enveloped RNA virus belonging to the genus respirovirus. The assessment of the virucidal activity of essential oils was performed according to the NF EN 14476 + A1 norm (janvier 2007, phase 2, étape 1) Essential oils, at 20 and 80% dilution, in contact with parainfluenza type 3 virus during 60 minutes at 20 °C, have a significant virucidal activity. This work confirms the interest and the relevance of the respiratory tract infections in vivo treatment with essential oils, which could complete the therapeutic choice and decrease antibiotic unnecessary use. Le traitement par les huiles essentielles des infections respiratoires limite le recours systématique aux antibiotiques (Phytothérapie 6 (2004) 175–9). Plusieurs virus sont responsables de ces infections virales respiratoires: virus influenza, virus respiratoire syncytial, virus para-influenzae, adénovirus, rhinovirus... Cette étude a consisté à mettre en évidence l’activité Virucide in vitro du produit Gouttes aux Essences®, complexe de cinq huiles essentielles vis-à-vis du virus para-influenzae de type 3, virus à ARN enveloppé appartenant au genre respirovirus. L’évaluation de l’activité Virucide des huiles essentielles a été réalisée selon la norme NF EN 14476 + A1 (janvier 2007, phase 2, étape 1). Les huiles essentielles diluées à 20 et 80 %, mises en contact avec le virus para-influenzae de type 3 durant 60 minutes à 20 °C, présentent une activité Virucide significative. Ce travail confirme l’intérêt et la pertinence de la prise en charge in vivo des infections virales respiratoires par les huiles essentielles qui peuvent ainsi compléter l’arsenal thérapeutique et limiter le recours indu aux antibiotiques.
Faris Q. Alenzi - One of the best experts on this subject based on the ideXlab platform.
-
Open Access Vaccines, Virucides and Drugs Against HIV/AIDS: Hopes and Optimisms for the Future
2016Co-Authors: Ali A. Al-jabri, Faris Q. AlenziAbstract:Abstract: More than 25 million lives have been claimed by AIDS and 33.2 million people are estimated to have HIV, the majority of which are living in the underdeveloped countries. Failed tests on vaccines, Virucides and complete virus eradi-cation have caused scientists to refocus on the basic questions of what makes an effective HIV immune response. The "gloom " over disappointing research results on vaccine development and Virucides "threatens to overshadow more posi-tive " HIV/AIDS-related news, such as findings that male circumcision might reduce the likelihood of HIV transmission and that giving antiretroviral drugs to "high-risk " HIV-negative people (pre-exposure prophylaxis) could help protect them from infection. Something like pre-exposure prophylaxis has a good chance of becoming available before we have a 100 % efficacious vaccine. The future in the field of HIV/AIDS will be much brighter if global research is appropriately coordinated and sufficient funds are available
-
Vaccines, Virucides and drugs against HIV/AIDS: hopes and optimisms for the future.
The Open AIDS Journal, 2009Co-Authors: Ali A. Al-jabri, Faris Q. AlenziAbstract:More than 25 million lives have been claimed by AIDS and 33.2 million people are estimated to have HIV, the majority of which are living in the underdeveloped countries. Failed tests on vaccines, Virucides and complete virus eradication have caused scientists to refocus on the basic questions of what makes an effective HIV immune response. The "gloom" over disappointing research results on vaccine development and Virucides "threatens to overshadow more positive" HIV/AIDS-related news, such as findings that male circumcision might reduce the likelihood of HIV transmission and that giving antiretroviral drugs to "high-risk" HIV-negative people (pre-exposure prophylaxis) could help protect them from infection. Something like pre-exposure prophylaxis has a good chance of becoming available before we have a 100% efficacious vaccine. The future in the field of HIV/AIDS will be much brighter if global research is appropriately coordinated and sufficient funds are available.
-
vaccines Virucides and drugs against hiv aids hopes and optimisms for the future
The Open Aids Journal, 2009Co-Authors: Ali A Aljabri, Faris Q. AlenziAbstract:More than 25 million lives have been claimed by AIDS and 33.2 million people are estimated to have HIV, the majority of which are living in the underdeveloped countries. Failed tests on vaccines, Virucides and complete virus eradication have caused scientists to refocus on the basic questions of what makes an effective HIV immune response. The "gloom" over disappointing research results on vaccine development and Virucides "threatens to overshadow more positive" HIV/AIDS-related news, such as findings that male circumcision might reduce the likelihood of HIV transmission and that giving antiretroviral drugs to "high-risk" HIV-negative people (pre-exposure prophylaxis) could help protect them from infection. Something like pre-exposure prophylaxis has a good chance of becoming available before we have a 100% efficacious vaccine. The future in the field of HIV/AIDS will be much brighter if global research is appropriately coordinated and sufficient funds are available.
Edward Trybala - One of the best experts on this subject based on the ideXlab platform.
-
Screening and Evaluation of Anti-respiratory Syncytial Virus Compounds in Cultured Cells
Antiviral Methods and Protocols, 2013Co-Authors: Anna Lundin, Tomas Bergström, Edward TrybalaAbstract:Respiratory syncytial virus (RSV) is a highly contagious pathogen that infects mainly ciliated cells of respiratory epithelium and type 1 pneumocytes in the alveoli frequently causing serious respiratory disease in infants, elderly, and immunocompromised patients. At present, prevention/treatment of RSV infection is limited to the use of specific anti-RSV antibody or an aerosol formulation of ribavirin, a drug of suboptimal efficacy and low safety profile. There is an urgent need for development of novel anti-RSV drugs and Virucides. Here we describe the cell culture-based methods used in our laboratory in identification of novel inhibitors of RSV including the P13 fusion inhibitor, and the PG545 Virucide. Protocols for antiviral screening, evaluation of anti-RSV potency, and elucidation of mode of antiviral activity of test compounds are described.
-
A highly lipophilic sulfated tetrasaccharide glycoside related to muparfostat (PI-88) exhibits virucidal activity against herpes simplex virus
Antiviral Research, 2010Co-Authors: Maria Ekblad, Tomas Bergström, Beata Adamiak, Ken D. Johnstone, Tomislav Karoli, Ligong Liu, Vito Ferro, Edward TrybalaAbstract:Although sulfated polysaccharides potently inhibit the infectivity of herpes simplex virus (HSV) and human immunodeficiency virus in cultured cells, these compounds fail to show protective effects in humans, most likely due to their poor virucidal activity. Herein we report on sulfated oligosaccharide glycosides related to muparfostat (formerly known as PI-88) and their assessment for anti-HSV activity. Chemical modifications based on the introduction of specific hydrophobic groups at the reducing end of a sulfated oligosaccharide chain enhanced the compound's capability to inhibit the infection of cells by HSV-1 and HSV-2 and abrogated the cell-to-cell transmission of HSV-2. Furthermore, modification with a highly lipophilic cholestanyl group provided a compound with virucidal activity against HSV. This glycoside targeted the viral particle and, to a lesser degree, the cell, and exhibited an antiviral mode of action typical for sulfated polysaccharides and Virucides, i.e., interference with the virus attachment to cells and irreversible inactivation of virus infectivity, respectively. The virucidal activity was decreased in the presence of human cervical secretions suggesting that higher doses of this glycoside might be needed for in vivo application. Altogether, the sulfated oligosaccharide-cholestanyl glycoside exhibits potent anti-HSV activity and is, therefore, a good candidate for development as a Virucide.
